These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1431 related items for PubMed ID: 30459435

  • 1. Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function.
    Zhang S, Shrestha CL, Kopp BT.
    Sci Rep; 2018 Nov 20; 8(1):17066. PubMed ID: 30459435
    [Abstract] [Full Text] [Related]

  • 2. Lumacaftor (VX-809) restores the ability of CF macrophages to phagocytose and kill Pseudomonas aeruginosa.
    Barnaby R, Koeppen K, Nymon A, Hampton TH, Berwin B, Ashare A, Stanton BA.
    Am J Physiol Lung Cell Mol Physiol; 2018 Mar 01; 314(3):L432-L438. PubMed ID: 29146575
    [Abstract] [Full Text] [Related]

  • 3. An "Unlikely" Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI.
    Schneider EK, Azad MA, Han ML, Tony Zhou Q, Wang J, Huang JX, Cooper MA, Doi Y, Baker MA, Bergen PJ, Muller MT, Li J, Velkov T.
    ACS Infect Dis; 2016 Jul 08; 2(7):478-88. PubMed ID: 27626100
    [Abstract] [Full Text] [Related]

  • 4. Altered iron metabolism in cystic fibrosis macrophages: the impact of CFTR modulators and implications for Pseudomonas aeruginosa survival.
    Hazlett HF, Hampton TH, Aridgides DS, Armstrong DA, Dessaint JA, Mellinger DL, Nymon AB, Ashare A.
    Sci Rep; 2020 Jul 02; 10(1):10935. PubMed ID: 32616918
    [Abstract] [Full Text] [Related]

  • 5. The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis.
    Sergeev V, Chou FY, Lam GY, Hamilton CM, Wilcox PG, Quon BS.
    Ann Am Thorac Soc; 2020 Feb 02; 17(2):147-154. PubMed ID: 31661636
    [Abstract] [Full Text] [Related]

  • 6. Anti-Infectives Restore ORKAMBI® Rescue of F508del-CFTR Function in Human Bronchial Epithelial Cells Infected with Clinical Strains of P. aeruginosa.
    Laselva O, Stone TA, Bear CE, Deber CM.
    Biomolecules; 2020 Feb 19; 10(2):. PubMed ID: 32092967
    [Abstract] [Full Text] [Related]

  • 7. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS.
    Ann Pharmacother; 2012 Feb 19; 46(7-8):1065-75. PubMed ID: 22739718
    [Abstract] [Full Text] [Related]

  • 8. Pathogen acquisition in patients with cystic fibrosis receiving ivacaftor or lumacaftor/ivacaftor.
    Singh SB, McLearn-Montz AJ, Milavetz F, Gates LK, Fox C, Murry LT, Sabus A, Porterfield HS, Fischer AJ.
    Pediatr Pulmonol; 2019 Aug 19; 54(8):1200-1208. PubMed ID: 31012285
    [Abstract] [Full Text] [Related]

  • 9. The use of lumacaftor/ivacaftor to treat acute deterioration in paediatric cystic fibrosis.
    Hammond JA, Connett GJ.
    Paediatr Respir Rev; 2018 Jun 19; 27():16-17. PubMed ID: 29914743
    [Abstract] [Full Text] [Related]

  • 10. Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy.
    Connett GJ.
    Drug Des Devel Ther; 2019 Jun 19; 13():2405-2412. PubMed ID: 31409974
    [Abstract] [Full Text] [Related]

  • 11. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study.
    Millar BC, Rendall JC, Downey DG, Moore JE.
    J Clin Pharm Ther; 2018 Dec 19; 43(6):836-843. PubMed ID: 29959786
    [Abstract] [Full Text] [Related]

  • 12. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel.
    Wu YS, Jiang J, Ahmadi S, Lew A, Laselva O, Xia S, Bartlett C, Ip W, Wellhauser L, Ouyang H, Gonska T, Moraes TJ, Bear CE.
    Mol Pharmacol; 2019 Oct 19; 96(4):515-525. PubMed ID: 31427400
    [Abstract] [Full Text] [Related]

  • 13. Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation.
    Meng X, Wang Y, Wang X, Wrennall JA, Rimington TL, Li H, Cai Z, Ford RC, Sheppard DN.
    J Biol Chem; 2017 Mar 03; 292(9):3706-3719. PubMed ID: 28087700
    [Abstract] [Full Text] [Related]

  • 14. Metabolomic responses to lumacaftor/ivacaftor in cystic fibrosis.
    Kopp BT, McCulloch S, Shrestha CL, Zhang S, Sarzynski L, Woodley FW, Hayes D.
    Pediatr Pulmonol; 2018 May 03; 53(5):583-591. PubMed ID: 29461009
    [Abstract] [Full Text] [Related]

  • 15. Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction.
    Brewington JJ, McPhail GL, Clancy JP.
    Expert Rev Respir Med; 2016 May 03; 10(1):5-17. PubMed ID: 26581802
    [Abstract] [Full Text] [Related]

  • 16. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K, Taylor-Cousar JL.
    Ther Adv Respir Dis; 2015 Dec 03; 9(6):313-26. PubMed ID: 26416827
    [Abstract] [Full Text] [Related]

  • 17. Modulators of CFTR. Updates on clinical development and future directions.
    Bardin E, Pastor A, Semeraro M, Golec A, Hayes K, Chevalier B, Berhal F, Prestat G, Hinzpeter A, Gravier-Pelletier C, Pranke I, Sermet-Gaudelus I.
    Eur J Med Chem; 2021 Mar 05; 213():113195. PubMed ID: 33524685
    [Abstract] [Full Text] [Related]

  • 18. Cystic fibrosis papers of the year 2017.
    Doull I.
    Paediatr Respir Rev; 2018 Jun 05; 27():2-5. PubMed ID: 29627168
    [Abstract] [Full Text] [Related]

  • 19. Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?
    Schneider EK, Reyes-Ortega F, Li J, Velkov T.
    Clin Pharmacol Ther; 2017 Jan 05; 101(1):130-141. PubMed ID: 27804127
    [Abstract] [Full Text] [Related]

  • 20. The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy.
    Lommatzsch ST, Taylor-Cousar JL.
    Ther Adv Respir Dis; 2019 Jan 05; 13():1753466619844424. PubMed ID: 31027466
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 72.